CHOP Researchers Discover Underlying Biology Behind Fontan-Associated Liver Disease

Findings provide some of the first evidence of potential therapeutic targets for condition affecting thousands of patients with single ventricle congenital heart disease

As patients with congenital heart diseases live longer, researchers are attempting to understand some of the other complications they may face as they age. In a new study, a team from Children’s Hospital of Philadelphia (CHOP) used state-of-the-art technologies to understand the underlying biology of Fontan-associated liver disease (FALD). The findings, published April 24, 2024 in Science Translational Medicine, reveal unprecedented insights into how the disease develops and potential therapeutic targets for future treatment options.

Login Or Register To Read Full Story